JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A SYSTMATIC REVIEW ON : SYNTHETIC VACCINES

DEVENDRA KUMAR SHAH, ASHISH KUMAR JAIN, AKHLESH KUMAR SINGHAI School of Pharmacy LNCT University Kolar Road, Bhopal M.P.(462042)

ABSTRACT :-

Synthetic vaccines, in particular long synthetic peptides of approximately 25–50 amino acids in length, are attractive for HIV vaccine development and for induction of therapeutic immune responses in patients with (pre)malignant disorders. In the case of preventive vaccine development against HIV, no major success has been achieved, but the possibilities are by no means exhausted. A long peptide vaccine consisting of 13 overlapping peptides, which together cover the entire length of the two oncogenic proteins E6 and E7 of high-risk human papilloma virus type 16 (HPV16), caused complete regression of all lesions and eradication of virus in 9 out of 20 women with high-grade vulvar intraepithelial neoplasia, a therapyresistant preneoplastic disorder. The nature and strength of the vaccineprompted T cell responses were significantly correlated with the clinical response. Synthetic peptide vaccines are attractive, because they allow rational improvement of vaccine design and detailed pharmacokinetic and pharmacodynamic studies not possible with conventional vaccines. Improvements are possible by addition or conjugation of adjuvants, notably TLR ligands, to the synthetic peptides.

Synthetic vaccines represent a groundbreaking approach in immunology, leveraging cutting-edge technologies to engineer targeted immune responses against specific pathogens. Unlike traditional vaccines derived from weakened or inactivated pathogens, synthetic vaccines are designed at the molecular level, often incorporating antigenic components of pathogens or mimics of these components. This design enables precise control over immune system activation, enhancing efficacy and safety profiles. Synthetic vaccines can be tailored to overcome challenges such as antigen variability and immunogenicity, offering potential solutions for diseases with complex or evolving pathogens. Additionally, their modular nature allows for rapid adaptation to emerging infectious threats, making them invaluable tools for pandemic preparedness. By harnessing synthetic biology, nanotechnology, and computational modeling, these vaccines hold promise for revolutionizing disease prevention and control in the 21st century.

KEYWORD:- Introduction, Composition, Mode of Action, Manufacturing Process, Clinical Trials, Market Availability, Research and Development.

***Corresponding Author-Email-** devendrashah341@gmail.com

1. INTRODUCTION OF SYNTHETIC VACCINES :-

In the landscape of modern medicine, synthetic vaccines represent a groundbreaking approach to disease prevention and control. Traditional vaccines typically involve weakened or inactivated forms of pathogens to stimulate an immune response. However, synthetic vaccines depart from this conventional paradigm by utilizing synthetic biology techniques to engineer novel vaccine constructs.

At their core, synthetic vaccines are meticulously designed to mimic the key antigenic components of pathogens, thus triggering a robust immune response without the need for live or attenuated pathogens. This innovative approach offers several advantages over traditional vaccines, including enhanced safety, scalability, and versatility.



Fig-01

The development of synthetic vaccines often begins with the identification of antigenic targets, such as surface proteins or unique molecular signatures, associated with a particular pathogen. Using advanced genetic engineering and synthetic biology tools, researchers can then design and synthesize custom-made vaccine antigens that precisely mimic these targets.

One of the defining features of synthetic vaccines is their modular nature, which allows for the incorporation of multiple antigenic components into a single vaccine formulation. This modular design facilitates the targeting of multiple strains or variants of a pathogen, as well as the inclusion of adjuvants or immunomodulatory molecules to enhance the immune response.

Moreover, synthetic vaccines offer unparalleled flexibility in antigen design and modification, enabling rapid adaptation to emerging infectious threats or changing epidemiological patterns. This agility is particularly valuable in the context of global pandemics, where timely vaccine development and deployment are critical for effective disease control.

Synthetic vaccines hold immense promise across a wide range of infectious diseases, including viral, bacterial, and parasitic infections. Additionally, they show potential in other areas of immunotherapy, such as cancer vaccines and therapeutic vaccines for chronic conditions.

As research in synthetic biology and vaccine design continues to advance, the potential applications of synthetic vaccines are poised to revolutionize the field of vaccinology and redefine our approach to disease prevention and control. Through continued innovation and collaboration, synthetic vaccines have the potential to address some of the most pressing global health challenges of the 21st century.

2. COMPOSITION :-

Synthetic vaccines are a type of vaccine that uses synthesized components, such as peptides or recombinant proteins, to trigger an immune response against specific pathogens. Here are some common components of synthetic vaccines.

Fig-02

Peptides:
Short chains of amino acids that mimic antigenic portions of pathogens. Peptides can be synthesized to represent specific epitopes (antigenic regions) of the pathogen, thus inducing an immune response against the pathogen.

Recombinant Proteins:
These are proteins produced through genetic engineering techniques where genes encoding antigenic proteins of pathogens are inserted into host cells, such as bacteria or yeast, to produce large quantities of the desired protein. These proteins can then be purified and used as vaccine components.

Virus-like Particles (VLPs):
These are self-assembled structures composed of viral structural proteins but lack the viral genetic material. VLPs resemble intact viruses, which makes them highly immunogenic without causing disease.

Nucleic Acids (DNA or RNA):
Synthetic vaccines can also include nucleic acids encoding antigenic proteins. These nucleic acids can be delivered directly into cells, where they are translated into proteins, thus stimulating an immune response.

Adjuvants:
These are substances added to vaccines to enhance the immune response. Adjuvants can be included in synthetic vaccines to improve their effectiveness by activating immune cells and prolonging the duration of the immune response.

Liposomes:
Liposomes are lipid-based nanoparticles that can encapsulate antigenic components of pathogens. They can serve as delivery vehicles for antigens, protecting them from degradation and enhancing their uptake by immune cells.

Conjugates:
Some synthetic vaccines may use conjugates, which are molecules that link antigenic components to carrier proteins. Conjugate vaccines are often used to enhance the immune response against polysaccharide antigens, which are otherwise poorly immunogenic.

Synthetic Carbohydrate Antigens:
Synthetic carbohydrates can be designed to mimic the surface structures of pathogens, such as polysaccharides. These synthetic antigens can be conjugated to carrier proteins to create glycoconjugate vaccines.

These components can be combined in various ways to design synthetic vaccines tailored to specific pathogens and diseases. Additionally, advancements in nanotechnology and immunology continue to expand the possibilities for synthetic vaccine development.

3. MODE OF ACTION :-

The mode of action of a synthetic vaccine depends on its design and immune response against a specific pathogen or disease. They can be designed using various approaches, such as recombinant DNA technology, peptide synthesis, or virus-like particle (VLP) assembly. Here's a simplified explanation of the general mode of action of a synthetic vaccine.



Fig-03

1. **Antigen Design :**
   Synthetic vaccines are designed to contain specific antigenic components of the target pathogen. These antigens could be proteins, peptides, or other molecules that are recognized by the immune system as foreign.

2. **Immune Recognition :**
   Once administered, the synthetic vaccine exposes the immune system to these antigenic components. Antigen-presenting cells (APCs), such as dendritic cells, phagocytose the antigens and present them to T cells and B cells.

3. **Activation of Immune Response:**
   T cells recognize the antigens presented by APCs and become activated. They release cytokines and stimulate B cells to produce antibodies specific to the antigens. This process primes the immune system to recognize and respond rapidly to the actual pathogen if encountered in the future.

4. **Antibody Production :**
   B cells differentiate into plasma cells, which produce large quantities of antibodies against the antigenic components of the synthetic vaccine. These antibodies can neutralize the pathogen or mark it for destruction by other immune cells.

5. **Memory Response :**
   Some activated T and B cells become memory cells, which persist in the body after the initial immune response subsides. These memory cells provide long-term immunity, allowing the immune system to mount a rapid and robust response upon re-exposure to the pathogen.Here's a simplified diagram illustrating the mode of action of a synthetic vaccine:

4. EFFICACY :-

The efficacy of a synthetic vaccine, like any vaccine, depends on several factors:

1. **Antigen Selection**:The antigen(s) chosen for the vaccine play a crucial role in determining its efficacy. Synthetic vaccines are designed to mimic specific antigens of pathogens, triggering an immune response. The efficacy can vary based on how well the chosen antigen(s) represent the target pathogen.

2. **Immune Response**: The ability of the vaccine to induce a robust and long-lasting immune response is critical. Synthetic vaccines should be designed to elicit both humoral (antibody-mediated) and cellular (T cellmediated) immune responses for optimal efficacy.

3. **Adjuvants**: Adjuvants are substances added to vaccines to enhance the immune response. They can improve efficacy by promoting a stronger and more prolonged immune response. Selecting the appropriate adjuvant for a synthetic vaccine formulation can significantly impact its effectiveness.

4. **Delivery System**: The delivery method of the vaccine can affect its efficacy. Synthetic vaccines may utilize various delivery systems, such as lipid nanoparticles or viral vectors, to efficiently deliver antigens and adjuvants to the immune system.

5. **Dosage and Schedule**: The dosage and vaccination schedule can influence the vaccine's efficacy. Ensuring the correct dosage and administration schedule is essential for achieving optimal immune responses and long-term protection.

6. **Population Factors**: The efficacy of a vaccine can vary among different populations due to factors such as age, health status, genetic diversity, and pre-existing immunity.

7. **Safety**: Safety is paramount in vaccine development. Synthetic vaccines must undergo rigorous testing to ensure they are safe for administration. Safety concerns can impact vaccine acceptance and ultimately its efficacy at a population level.

Overall, synthetic vaccines have the potential to be highly efficacious, especially when carefully designed and optimized using the latest advances in immunology, molecular biology, and vaccine technology. However, thorough preclinical and clinical testing is necessary to determine their efficacy and safety profiles before widespread use.

5. SAFETY PROFILE :-

The safety profile of synthetic vaccines represents a critical aspect in their development, deployment, and widespread use. Synthetic vaccines, engineered through innovative technologies such as recombinant DNA techniques or synthetic biology, undergo rigorous safety evaluations throughout their lifecycle.

During the preclinical phase, extensive laboratory studies and animal trials are conducted to assess the vaccine's safety profile before advancing to human trials. These studies aim to identify any potential toxicities, immunogenicity, or adverse effects associated with the vaccine candidate.



Fig-04

Human clinical trials further elucidate the safety profile of synthetic vaccines. These trials, conducted in multiple phases, involve carefully monitored administration to human volunteers. Adverse events are closely monitored and documented, allowing researchers to assess the vaccine's safety profile under controlled conditions. Any adverse reactions are thoroughly investigated to determine their causality and severity.

Post-marketing surveillance plays a crucial role in continuously monitoring the safety profile of synthetic vaccines once they are approved and distributed for public use. Healthcare systems employ various surveillance mechanisms to detect and evaluate adverse events following vaccination. This ongoing surveillance helps identify rare or unexpected adverse reactions that may not have been evident during clinical trials.

Regulatory agencies work closely with manufacturers and healthcare providers to ensure that any safety concerns related to synthetic vaccines are promptly addressed. This collaborative effort involves the dissemination of safety information, implementation of risk management strategies, and, if necessary, modification or withdrawal of the vaccine.

6. MANUFACTURING PROCESS :-

The manufacturing process for synthetic vaccines can vary depending on the type of vaccine being produced (e.g., mRNA, protein subunit, virus-like particles, etc.), but here's a general overview of the process.



Fig-05

i Selection of Antigen:
The first step in manufacturing a synthetic vaccine is selecting the antigen(s) that will trigger an immune response against the target pathogen. Antigens can be proteins, peptides, or other molecules that are specific to the pathogen.

ii Gene Synthesis or Isolation:
If the antigen is a protein or peptide, its gene sequence can be synthesized artificially or isolated from the pathogen.

iii Insertion into Expression System:
Once the gene sequence encoding the antigen is available, it needs to be inserted into an appropriate expression system. For synthetic vaccines, common expression systems include bacteria (e.g., E. coli), yeast (e.g., Saccharomyces cerevisiae), insect cells (e.g., baculovirus expression system), or mammalian cells (e.g., Chinese hamster ovary cells).

iv Expression and Purification: After the gene has been inserted into the expression system, the cells are cultured under controlled conditions to produce the antigen. The antigen is then purified from the cell lysate or culture medium using various purification techniques such as chromatography, filtration, and centrifugation.

v Formulation:
Once purified, the antigen is formulated into the final vaccine product. This may involve combining the antigen with adjuvants, stabilizers, preservatives, and other ingredients to enhance its stability, immunogenicity, and shelf-life.

vi Quality Control:
Throughout the manufacturing process, rigorous quality control tests are conducted to ensure the safety, purity, and potency of the vaccine. This includes testing for contaminants, verifying the identity and integrity of the antigen, and assessing its immunogenicity.

vii Fill and Finish:
After passing quality control tests, the vaccine is filled into vials, syringes, or other delivery devices and labeled with appropriate information such as dosage, expiration date, and batch number.

viii Packaging and Distribution:
The filled and finished vaccines are then packaged into boxes or cartons and distributed to healthcare facilities, Pharmacies, and other distribution points for administration to patients.

ix Regulatory Approval:
Before the vaccine can be marketed and distributed, it must receive regulatory approval from the appropriate authorities (e.g., FDA in the United States, EMA in Europe). This involves submitting comprehensive data on the vaccine's safety, efficacy, and quality, as well as evidence of compliance with regulatory standards and requirements.

x Post-Market Surveillance:
Even after regulatory approval, ongoing monitoring of the vaccine's safety and effectiveness is essential through post-market surveillance programs. This helps to detect and investigate any adverse events or unexpected side effects that may occur after vaccination.

7. RESEARCH AND DEVELOPMENT :-

Research and development for synthetic vaccines involves a multidisciplinary approach that combines expertise in immunology, molecular biology, bioinformatics, and synthetic biology. Synthetic vaccines are designed to elicit an immune response against specific pathogens by presenting antigenic components in a controlled manner. Here's an overview of the key steps involved in the research and development process:

Fig-06

i **Identification of Target Pathogens**:
The first step is to identify the pathogen or pathogens against which the vaccine will be developed. This may involve surveillance of infectious diseases, epidemiological studies, and genomic analysis of pathogens to identify potential vaccine targets.

ii **Antigen Selection**:
Once the target pathogen is identified, researchers select suitable antigenic components for inclusion in the vaccine. These antigens should be immunogenic and capable of inducing a protective immune response. Bioinformatics tools and computational modeling can aid in predicting antigenic epitopes.

iii **Design of Synthetic Constructs**:
Synthetic vaccines often utilize recombinant DNA technology to produce antigenic constructs. This may involve designing DNA sequences encoding the selected antigens and incorporating them into expression vectors for protein production. Alternatively, synthetic peptides or mimotopes can be designed to mimic antigenic epitopes.

iv **Expression and Production**:
The synthetic constructs are then expressed in suitable host systems, such as bacteria, yeast, or mammalian cells, to produce the antigenic proteins or peptides. Expression systems may vary depending on factors such as protein folding, post-translational modifications, and scalability.

v **Formulation**:
The antigens are formulated with adjuvants and other components to enhance their immunogenicity and stability. Formulation strategies may include liposomes, nanoparticles, or other delivery systems to improve antigen presentation and immune response.

vi **Preclinical Testing**:
The formulated vaccine candidates undergo preclinical testing in animal models to evaluate safety, immunogenicity, and efficacy. These studies assess parameters such as antibody titers, cellular immune responses, and protection against challenge with the target pathogen.

vii **Clinical Trials**:
If preclinical studies demonstrate promising results, the vaccine candidates advance to clinical trials in humans. Clinical trials involve multiple phases, including Phase I (safety), Phase II (immunogenicity and dosage optimization), and Phase III (efficacy and safety in larger populations). Regulatory agencies closely oversee the clinical development process to ensure safety and efficacy.

viii **Regulatory Approval**:
Upon successful completion of clinical trials, regulatory approval is sought from health authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Regulatory approval requires comprehensive data demonstrating the safety, efficacy, and quality of the vaccine.

ix **Manufacturing and Distribution**:
Once regulatory approval is obtained, the vaccine is manufactured at scale and distributed for widespread use. Manufacturing processes must adhere to Good Manufacturing Practice (GMP) standards to ensure consistency, quality, and safety of the vaccine products.

8. CLINICAL TRIALS :-

Conducting clinical trials for synthetic vaccines follows a structured process, which typically involves several phases to ensure safety and efficacy. Here's a general outline of the steps involved:



Fig-07

Preclinical Research:-
Before human trials, extensive preclinical research is conducted in laboratories and on animals to understand the vaccine's safety profile, its mechanism of action, and its potential efficacy. This phase also helps in determining the appropriate dosage levels for human trials.

Phase 1 Clinical Trial:-

- **Objective**: The primary goal of Phase 1 trials is to evaluate the safety of the synthetic vaccine in a small group of healthy volunteers.
- **Participants**: Generally involves a small number of volunteers (usually between 20 to 100).
- **Duration**: Typically lasts several months.
- **Outcome**: Investigators closely monitor participants for any adverse reactions and assess the vaccine's tolerability and safety profile. Additionally, they may also evaluate the immune response generated by the vaccine.

Phase 2 Clinical Trial:-

- **Objective**: The main goal of Phase 2 trials is to further assess the vaccine's safety and efficacy in a larger group of participants.
- **Participants**: Involves several hundred volunteers, including individuals from the target population (e.g., those at risk of the disease).
- **Duration**: Can last from several months to a few years.
- **Outcome**: Researchers closely monitor participants for adverse reactions, evaluate the immune response, and gather preliminary data on the vaccine's efficacy in preventing the disease.

Phase 3 Clinical Trial:-

- **Objective**: Phase 3 trials aim to confirm the vaccine's safety and efficacy on a larger scale and in more diverse populations.
- **Participants**: Involves thousands to tens of thousands of participants, including individuals from different demographic groups and regions.
- **Duration**: Typically lasts several years.
- **Outcome**: Researchers continue to monitor safety, evaluate efficacy, and collect data on long-term effects. These trials also provide more robust evidence of the vaccine's effectiveness and safety profile.



Fig-08

9. REGULATORY APPROVAL :-

Regulatory approval for synthetic vaccines follows a stringent process to ensure their safety, efficacy, and quality before they reach the public. Unlike traditional vaccines, which are often derived from weakened or inactivated pathogens, synthetic vaccines are designed using molecular techniques to mimic the structure of specific antigens or proteins associated with a disease.

Fig-09

The regulatory pathway for synthetic vaccines typically begins with extensive preclinical testing. In this phase, researchers conduct laboratory experiments and animal studies to assess the vaccine's immunogenicity, toxicity profile, and potential side effects. Data from these studies are crucial for informing further development and providing evidence of safety before human trials can commence.

Once preclinical testing demonstrates promising results, developers submit an Investigational New Drug (IND) application to regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). This application includes detailed information about the vaccine's composition, manufacturing process, preclinical data, and proposed clinical trial plans.

Clinical trials for synthetic vaccines typically follow the standard phases of investigation: Phase 1, Phase 2, and Phase 3. Phase 1 trials involve a small number of healthy volunteers and primarily assess safety and dosage. Phase 2 trials expand the participant pool to evaluate efficacy and further explore safety considerations. Finally, Phase 3 trials enroll thousands of individuals to confirm efficacy, monitor adverse reactions, and gather additional safety data.

Upon completion of clinical trials, developers compile all relevant data into a New Drug Application (NDA) or Biologics License Application (BLA) for submission to regulatory authorities. This comprehensive dossier includes detailed information on the vaccine's safety profile, efficacy data from clinical trials, manufacturing processes, and quality control measures.

Regulatory agencies meticulously review the submitted data to assess the vaccine's safety, efficacy, and manufacturing consistency. Expert committees may be convened to provide independent evaluation and recommendations. The regulatory review process aims to ensure that the vaccine meets rigorous standards for approval or authorization, balancing the benefits of immunization with potential risks.

If the synthetic vaccine meets regulatory criteria, it receives approval or authorization for marketing and distribution. However, the process does not end with approval. Post-marketing surveillance programs continue to monitor the vaccine's safety and effectiveness in real-world settings, enabling regulators to detect any unexpected adverse events and ensure ongoing public health protection.

10. MARKET AVAILABILITY :-

last update in January 2022, synthetic vaccines, particularly mRNA vaccines like those developed by Pfizer-BioNTech and Moderna for COVID-19, had received emergency use authorization in many countries around the world. These vaccines were being distributed globally through various channels, including government vaccination programs, healthcare facilities, pharmacies, and vaccination centers.

Fig-10

Distribution efforts have varied depending on factors such as:

- **Regulatory Approval**: Vaccines must receive regulatory approval or emergency use authorization from relevant authorities in each country before distribution can commence.
- **Manufacturing Capacity**: The production capacity of vaccine manufacturers plays a crucial role in determining the availability and distribution of vaccines. Companies have been scaling up production to meet global demand.
- **Supply Chains**: Distribution networks, cold chain logistics, and storage infrastructure are essential for transporting and storing vaccines, especially those with specific temperature requirements like mRNA vaccines.
- **Government Policies and Agreements**: Governments negotiate procurement deals with vaccine manufacturers and coordinate distribution efforts through national vaccination programs or collaborations with international organizations such as COVAX.
- **Priority Groups**: Initially, vaccines were prioritized for certain populations, such as healthcare workers, the elderly, and individuals with underlying health conditions, before becoming more widely available to the general population.
- **Public Education and Outreach**: Public health campaigns are crucial for disseminating information about vaccine availability, safety, and the importance of vaccination in controlling the spread of infectious diseases.

For the most up-to-date information on the availability and distribution of synthetic vaccines, I recommend consulting official sources such as government health departments, the World Health Organization (WHO), and vaccine manufacturers' announcements. Additionally, local healthcare providers and vaccination centers can provide information on vaccine availability in specific regions.

11. CONCLUSION :-

In conclusion, the development and utilization of synthetic vaccines represent a significant stride forward in the field of immunization. These vaccines, crafted with precision through synthetic biology techniques, offer a promising avenue for combating a diverse array of infectious diseases. Their potential lies not only in their ability to provide effective immunity but also in their adaptability to evolving pathogens and antigenic variations.

However, realizing the full potential of synthetic vaccines requires continued research, rigorous testing, and regulatory approval. Transparency and communication efforts are essential to garner public trust and acceptance of these novel vaccine technologies. Collaborative efforts among researchers, industry partners, and regulatory agencies are vital to navigate the complexities of synthetic vaccine development and ensure their widespread implementation for global health benefits.

In essence, synthetic vaccines offer a promising pathway towards more effective and adaptable immunization strategies, poised to address current and future infectious disease challenges with precision and efficiency.

12. REFERENCES :-

1. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater. 2013;12(11):978-990. doi:10.1038/nmat3775
2. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi:10.1038/nrd.2017.243
3. Kanekiyo M, Wei CJ, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499(7456):102-106. doi:10.1038/nature12202
4. Moon JJ, Suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater. 2011;10(3):243-251. doi:10.1038/nmat2960
5. De Gregorio E, Rappuoli R. Vaccines for the future: learning from human immunology. Microb Biotechnol. 2012;5(2):149-155. doi:10.1111/j.1751-7915.2011.00300.x
6. Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14(5):289-301. doi:10.1038/nri3646
7. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109-11146. doi:10.1021/acs.chemrev.5b00109
8. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6(3):381-390. doi:10.1586/14760584.6.3.381
9. Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide vaccine: progress and challenges. Vaccines (Basel). 2014;2(3):515-536. doi:10.3390/vaccines2030515
10. Lewis GK. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?. Expert Rev Vaccines. 2016;15(10):1223-1234. doi:10.1080/14760584.2016.1196834
11. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8(20):934-943. doi:10.1016/S1359-6446(03)02889-1
12. Wang C, Liu Y, Cao Z, et al. Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses. Sci Rep. 2018;8(1):6723. doi:10.1038/s41598-018-25219-0
13. Xu L, Liu Y, Chen Z, et al. Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett. 2012;12(4):2003-2012. doi:10.1021/nl204496b
14. Poonia B, Charan S, Singh B, et al. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J Nanobiotechnology. 2015;13:59. doi:10.1186/s12951-0150117-1
15. Wang J, Wang J, Dai H, et al. Oral Vaccination with a LiposomeEncapsulated Influenza DNA Vaccine Protects Mice against Respiratory Challenge Infection. J Med Virol. 2016;88(10):1734-1741. doi:10.1002/jmv.24497
16. Wadman M. Synthetic biology faces high hopes—and fears. Science. 2019;363(6427):1160-1163. doi:10.1126/science.363.6427.1160
17. Ghasemi Y, Mohammadi M, Ebrahimi M, Hashemi A, Vaziri F. Conjugation of B and T cell epitopes of the HER2/neu oncogene to polyionic platforms for cancer vaccine design: Synthesis and in vitro evaluation. Int J Pharm. 2016;513(1-2):642-652. doi:10.1016/j.ijpharm.2016.09.059

18. Wang Y, Wang X, Liang R, et al. An effective cancer vaccine modality: antigen-presenting cell-pulsed intratumoral polymeric nanoparticles. J Control Release. 2018;292:88-96. doi:10.1016/j.jconrel.2018.11.015

19. Muraoka D, Harada N, Hayashi T, et al. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest. 2019;129(3):1278-1294. doi:10.1172/JCI123791

20. He L, Zhou W, Li X, et al. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. Vaccine. 2014;32(29):3672-3679. doi:10.1016/j.vaccine.2014.04.075

21. Naskalska A, Pyrc K. Virus like particles as immunogens and universal nanocarriers. Pol J Microbiol. 2015;64(1):3-13.

22. Slutter B, Bal SM, Que I, et al. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?. Mol Pharm. 2010;7(6):2207-2215. doi:10.1021/mp100261m

23. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915-928. doi:10.1016/j.addr.2007.08.044

24. Amini Y, Amjad MW, Ramezani M, Adelzadeh M, Gholami S, Eslami S. Nanoadjuvants and their Application in Mucosal Vaccines. Biointerface Res Appl Chem. 2020;10(6):6838-6855. doi:10.33263/BRIAC106.838855

25. Roden R, Wu TC. How will HPV vaccines affect cervical cancer?. Nat Rev Cancer. 2006;6(10):753-763. doi:10.1038/nrc1972

26. Maeda K, Schur MJ, Tsai IJ, et al. Enhancement of mucosal immunogenicity of viral vectored vaccines by the NKT cell agonist alpha-galactosylceramide as adjuvant. Vaccines (Basel). 2019;7(4):161. doi:10.3390/vaccines7040161

27. Unsoy G, Gunduz U. Smart drug delivery systems in cancer therapy. Curr Drug Targets. 2018;19(3):202-212. doi:10.2174/1389450119666180105151230

28. González-Aramundiz JV, Presas E, Dalmau-Mena I, et al. Biomaterials for mucosal vaccine delivery. Eur J Pharm Sci. 2018;115:67-83. doi:10.1016/j.ejps.2017.12.036

29. Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114:116-131. doi:10.1016/j.addr.2016.11.012

30. Scott EA, Stano A, Gillard M, et al. Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes. Biomaterials. 2012;33(26):6211-6219. doi:10.1016/j.biomaterials.2012.04.061

31. Kim HK, Davaa E, Myung CS, Park JS. Synthesis and characterization of alginate nanoparticles for colon-targeted drug delivery using mixed solvent system. J Microencapsul. 2008;25(7):539-547. doi:10.1080/02652040802014347

32. HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2013;3:406. doi:10.3389/fimmu.2012.00406

33. Buckland B, Boulanger R, Fino M, Srivastava I, Holtz K. New technologies for influenza vaccines. Microbiol Spectr. 2016;4(6). doi:10.1128/microbiolspec.EI10-0015-2016

34. Huang Z, Shi L, Ma J, et al. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vaccin Immunother. 2019;15(2):285-292. doi:10.1080/21645515.2018.1553476

35. Blasi P, Bortolotti F, Bonifazi D, et al. Polysaccharides as vaccine adjuvants. Eur J Pharm Sci. 2017;98:66-71. doi:10.1016/j.ejps.2016.10.014

36. DeGregorio E, Caproni E, Ulmer JB. Vaccine adjuvants: mode of action. Front Immunol. 2013;4:214. doi:10.3389/fimmu.2013.00214

37. Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med. 2011;1(1):a007252. doi:10.1101/cshperspect.a007252

38. Lua LH, Connors NK, Sainsbury F, Chuan YP, Wibowo N, Middelberg AP. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng.2014;111(3):425-440. doi:10.1002/bit.25132

39. Garçon N, Segal L, Tavares F, Van Mechelen M. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine. 2011;29(27):4453-4459. doi:10.1016/j.vaccine.2011.04.094

40. McCray PB Jr, Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813-821. doi:10.1128/JVI.02012-06

41. Wang X, Ren J, Gao Q, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592(7855):616-622. doi:10.1038/s41586-021-03412-7

42. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-527. doi:10.1038/s41586-020-2798-3

43. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920-1931. doi:10.1056/NEJMoa2022483

44. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577

45. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389

46. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of SingleDose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544

47. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-594. doi:10.1056/NEJMoa2108891

48. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet. 2021;397(10278):952-954. doi:10.1016/S0140-6736(21)00370-6

49. World Health Organization. Ten threats to global health in 2019. Published January 2019. Accessed April 5, 2024.

50. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759-780. doi:10.1038/nrd4278